Drug Profile
Research programme: cancer therapeutics - Highlight Therapeutics
Alternative Names: BO-011; BO-110Latest Information Update: 21 Apr 2020
Price :
$50
*
At a glance
- Originator Bioncotech Therapeutics
- Developer Highlight Therapeutics
- Class
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Autophagy stimulants; Ephrin-B2 antagonists; IFIH1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Apr 2020 Bioncotech Therapeutics is now called Highlight Therapeutics
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in Spain
- 08 Jan 2014 Preclinical trials in Cancer in Spain (unspecified route) prior to January 2014